Adding ruxolitinib to transplant preparation for sickle cell disease
Tests adding ruxolitinib to transplant preparation in young people with sickle cell disease.
Key facts
- Who runs it
- Arkansas Children's Hospital Research Institute
- Where
- Atlanta, Aurora, New Orleans, and Philadelphia, United StatesSee the 4 sites
- Trial code
- Registry title
- Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 24 people, planned
- Started
- 8 Jun 2026
- Expected to end
- 19 Nov 2029
- Type of study
- Interventional
- Treatments tested
- Ruxolitinib
- Record updated
- 4 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people aged 12 to 45 with sickle cell disease and serious complications. They need a half-matched family donor for a bone marrow transplant.
- Age
- 12 to 45 years
- Sex
- All sexes can join.
- Disease stage
- Sickle cell disease of any genetic type with at least one of these: past stroke or blood vessel disease, repeated moderate-severe acute chest syndrome, repeated painful crises needing injected pain medicine, regular blood transfusions to prevent complications, or (adults) a raised tricuspid valve jet velocity of 2.7 m/sec or more on heart ultrasound.
- Earlier treatment
- No previous stem-cell transplant or solid organ transplant.
- Biomarker or test result
- A first-degree relative (parent, sibling or half sibling) who is half-matched (haploidentical) and willing to donate bone marrow. High levels of antibodies against the donor's tissue type are not allowed without study chair approval.
Main reasons for not taking part
- A fully tissue-matched sibling who can donate bone marrow
- Uncontrolled infection, active TB, hepatitis B or C, or HIV
- Previous stem-cell or solid organ transplant
- Current pregnancy or breastfeeding
- History of cancer, except resected basal cell carcinoma or treated carcinoma in situ
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Participants with any genotypic form of SCD aged 12 - 45 years at enrollment with ≥1 of the following:; History of stroke and/or vasculopathy, including evidence of asymptomatic cerebrovascular disease for pediatric patients; Recurrent moderate-severe acute chest syndrome (ACS); Recurrent vaso-occlusive pain episodes requiring parenteral analgesia despite the institution of supportive care; Need for chronic transfusion therapy to prevent vaso-occlusive complications (i.e. pain, stroke, and ACS); For adult patients, an echocardiographic finding of tricuspid valve regurgitant jet velocity (TRJV) ≥ 2.7 m/sec
- Participants must have an HLA haploidentical first degree relative (parent, sibling, or half sibling) who is willing and able to donate bone marrow
- Participants must meet institutional eligibility criteria for HCT
Who cannot take part
- Previous HCT or solid organ transplant
- Use of medications which significantly interfere with ruxolitinib metabolism
- Inability to swallow and retain oral medication (use of nasogastric or gastrostomy tube permitted)
- Participation in another clinical trial involving an investigational or off-label use of a drug or device in the past 3 months
- High-titer anti-donor specific HLA antibodies (without review and approval by Study Chair)
- Uncontrolled infection, evidence of active TB, Hepatitis B or C infection, or HIV seropositivity or infection
- CNS revascularization procedure, myocardial infarction, pulmonary embolus or deep vein thrombosis in the past 6 months
- Known hypersensitivity or severe reaction to ruxolitinib or any component of the conditioning regimen or its excipients
- History of malignancy except resected basal cell carcinoma or treated carcinoma in-situ
- Clinically significant, uncontrolled autoimmune disease
- Any condition that would, in the investigator's judgment, interfere with full participation in the study, pose a significant risk to the subject, or interfere with interpretation of study data
- Presence of an HLA-matched sibling who is willing and able to donate bone marrow
- Currently pregnant or breast feeding
- Participant (or guardian) inability or unwillingness to comply with the dose schedule and study evaluations, comprehend or sign informed consent and utilize a highly effective method of contraception (for participants of child-bearing potential)
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 12 and 45 years old?
Where in United States
- Children's Healthcare of AtlantaAtlanta, United StatesContact: Julia GliwinskiTaking people
- Children's Hospital of ColoradoAurora, United StatesContact: Chris McKinney, MD (principal investigator)Not yet recruiting
- Manning Family Children'sNew Orleans, United StatesContact: Wyvonnia WalkerNot yet recruiting
- Children's Hospital of PhiladelphiaPhiladelphia, United StatesContact: Nykirah TurnerNot yet recruiting
About the trial
What the trial wants to find out
This trial will determine whether adding ruxolitinib to a reduced intensity conditioning (RIC) regimen reduces the rate of graft failure following haploidentical (haplo) hematopoietic cell transplant (HCT) for children and young adults with sickle cell disease (SCD).
Read full original descriptionShow less
This study will enroll and treat up to 24 participants. Recruitment is expected to last for about 2 years and participants will be followed for an additional 2 years post-HCT.
The group in the trial
- Ruxolitinib-Enhanced RICTreatment being tested
Pediatric and young adult participants who are undergoing haplo HCT for SCD will receive RIC with fludarabine, cyclophosphamide, thiotepa, ATG and low-dose TBI along with ruxolitinib. Ruxolitinib will continue post-HCT in addition to post-transplant cyclophosphamide and sirolimus or a calcineurin inhibitor for GVHD prophylaxis.
Treatment: Ruxolitinib
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Ruxolitinib-Enhanced Conditioning for Pediatric and Young Adult Patients With Symptomatic Sickle Cell Disease Undergoing Haploidentical Hematopoietic Cell Transplantation
- Plain-language title
- Adding ruxolitinib to transplant preparation for sickle cell diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT07252050, who can take part
- Record updated
- 4 June 2026